Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation
Tanios Bekaii‐Saab, Rona Yaeger, Alexander I. Spira, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 25, pp. 4097-4106
Open Access | Times Cited: 140

Showing 1-25 of 140 citing articles:

Targeting KRAS in cancer
Anupriya Singhal, Bob T. Li, Eileen M. O’Reilly
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 969-983
Closed Access | Times Cited: 67
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
Urszula N. Wasko, Jingjing Jiang, Tanner C. Dalton, et al.
Nature (2024) Vol. 629, Iss. 8013, pp. 927-936
Open Access | Times Cited: 55
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Míriam Molina‐Arcas, Julian Downward
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 338-357
Open Access | Times Cited: 46
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
Abdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 38
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Julien Dilly, Megan T. Hoffman, Laleh Abbassi, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2135-2161
Closed Access | Times Cited: 36
Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
Rona Yaeger, Nataliya V. Uboha, Meredith S. Pelster, et al.
Cancer Discovery (2024) Vol. 14, Iss. 6, pp. 982-993
Open Access | Times Cited: 28
The evolving landscape of tissue‐agnostic therapies in precision oncology
Vivek Subbiah, Mohamed A. Gouda, Bettina Ryll, et al.
CA A Cancer Journal for Clinicians (2024) Vol. 74, Iss. 5, pp. 433-452
Open Access | Times Cited: 19
Targeting KRAS in pancreatic cancer
Sandra Stickler, Barbara H. Rath, Gerhard Hamilton
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2024) Vol. 32, Iss. 5, pp. 799-805
Open Access | Times Cited: 18
KRAS G12C inhibitor combination therapies: current evidence and challenge
Hirotaka Miyashita, Shumei Kato, David S. Hong
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 15
KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma
Carter Norton, Matthew Shaw, Zachary Rubnitz, et al.
JAMA Network Open (2025) Vol. 8, Iss. 1, pp. e2453588-e2453588
Open Access | Times Cited: 2
A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer
Daoyan Wei, Liang Wang, Xiangsheng Zuo, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 4, pp. 655-662
Open Access | Times Cited: 35
Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies
Anna Linehan, Mary O’Reilly, Ray McDermott, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 13
Next-generation therapies for pancreatic cancer
Conor Buckley, Eileen M. O’Reilly
Expert Review of Gastroenterology & Hepatology (2024) Vol. 18, Iss. 1-3, pp. 55-72
Open Access | Times Cited: 11
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
Caicun Zhou, Chongyang Li, Libo Luo, et al.
Cancer Cell (2024) Vol. 42, Iss. 7, pp. 1286-1300.e8
Closed Access | Times Cited: 11
The Clinical Implications of KRAS Mutations and Variant Allele Frequencies in Pancreatic Ductal Adenocarcinoma
Faria Nusrat, Akshay Khanna, Aditi Jain, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 7, pp. 2103-2103
Open Access | Times Cited: 9
A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer
Anupriya Singhal, Hannah C. Styers, Jonathan Rub, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2122-2134
Closed Access | Times Cited: 9
Consensus, debate, and prospective on pancreatic cancer treatments
Junke Wang, Jie Yang, Amol Narang, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 9
Impact of KRAS mutation on the tumor microenvironment in colorectal cancer
Yiru Zhou, Yeye Kuang, Chan Wang, et al.
International Journal of Biological Sciences (2024) Vol. 20, Iss. 5, pp. 1947-1964
Open Access | Times Cited: 8
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Sílvia Casacuberta‐Serra, Íñigo González-Larreategui, Daniel Capitán-Leo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 8
Digestive cancers: mechanisms, therapeutics and management
Tianzuo Zhan, Johannes Betge, Nadine Schulte, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors
Jakob M. Riedl, Ferran Fece de la Cruz, W. Marston Linehan, et al.
Annals of Oncology (2025)
Open Access | Times Cited: 1
New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe
Lorenza Rimassa, Ángela Lamarca, Grainne M. O’Kane, et al.
The Lancet Regional Health - Europe (2025) Vol. 50, pp. 101170-101170
Open Access | Times Cited: 1
Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure
Victor Hugo Fonseca de Jesus, Maria Cecília Mathias-Machado, João Paulo Fogacci de Farias, et al.
Cancers (2023) Vol. 15, Iss. 20, pp. 5015-5015
Open Access | Times Cited: 17
Current Standards, Multidisciplinary Approaches, and Future Directions in the Management of Extrahepatic Cholangiocarcinoma
Margaret Wheless, Rajiv Agarwal, Laura W. Goff, et al.
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 1, pp. 127-160
Open Access | Times Cited: 7
Unresectable biliary tract cancer: Current and future systemic therapy
Danmei Zhang, Klara Dorman, C. Benedikt Westphalen, et al.
European Journal of Cancer (2024) Vol. 203, pp. 114046-114046
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top